Results 101 to 110 of about 11,984 (174)

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis

open access: yesCancer, Volume 132, Issue 19, 1 October 2026.
Abstract Background Ciltacabtagene autoleucel (cilta‐cel), an anti–B‐cell maturation antigen (BCMA) chimeric antigen receptor T‐cell (CAR‐T) therapy, is approved for relapsed/refractory multiple myeloma (RRMM). Methods Using the Center for International Blood and Marrow Transplant Research registry, this study evaluated outcomes of frail patients ...
Hira Mian   +31 more
wiley   +1 more source

The Multiple Myeloma - Extramedullary Manifestations [PDF]

open access: yes
The second most common hematologic malignancy is the clonal proliferation of neoplastic plasma cells within the bone marrow. There is the presence of monoclonal immunoglobulins in the serum and/or urine.
Nöldge, Gerd   +4 more
core   +1 more source

What Is Your Diagnosis? Blood Smear From a Mixed‐Breed Dog

open access: yes
Veterinary Clinical Pathology, EarlyView.
Laura S. Peres   +5 more
wiley   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation Achieves Durable Remission in Blast‐Phase Chronic Myeloid Leukemia Presenting as Early T‐Cell Precursor Acute Lymphoblastic Leukemia

open access: yeseJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Introduction The presentation of chronic myeloid leukemia (CML) in the blast phase as early T‐cell precursor acute lymphoblastic leukemia (ETP‐ALL) is very rare. As previously reported, in contrast to B‐ALL, the prognosis is poor. Case Presentation We encountered a patient with blast phase CML presenting as ETP‐ALL.
Takafumi Tsushima   +10 more
wiley   +1 more source

Hepatic nodule: a case of primary myelofibrosis

open access: yes, 2012
Primary myelofibrosis is one of the entities that may manifest with lesions of extramedullary haematopoiesis, especially in spleen and liver. The authors report a case of primary myelofibrosis presenting incidentally as an intrahepatic focal lesion of ...
Pires, J   +3 more
core   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

open access: yesMedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta   +2 more
wiley   +1 more source

Third Allogeneic Stem Cell Transplantation in Children: A Multicenter Analysis From the Spanish GETH‐TC Pediatric Group

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 943-952, October 2026.
ABSTRACT Third allogeneic hematopoietic stem cell transplantation (HSCT3) is rarely performed in pediatric patients and is associated with high toxicity and mortality. Data on outcomes in this setting remain scarce. We conducted a retrospective multicenter study within the Spanish GETH‐TC Pediatric group including 29 children and adolescents who ...
Luisa Sisinni   +17 more
wiley   +1 more source

Updates and controversies in contemporary grading of clear cell renal cell carcinoma and papillary renal cell carcinoma

open access: yesHistopathology, Volume 89, Issue 4, Page 574-589, October 2026.
New concepts, innovations and some issues have emerged since the adoption a decade ago of WHO/ISUP grading for CCRCC and PRCC. Continued use of the WHO/ISUP grading for CCRCC and PRCC has been upheld by newer studies, and practice guidance for some of the grading issues, where data are available, is provided.
Gladell P. Paner   +4 more
wiley   +1 more source

Haematopoiesis in Marsupials

open access: yes, 2016
Marsupials are a group of mammals that give birth to immature young lacking mature immune tissues at birth, and are unable to mount their own specific immune defence.
Old, Julie M. (R11445), Julie M. Old
core   +1 more source

Home - About - Disclaimer - Privacy